Your browser is no longer supported. Please, upgrade your browser.
Settings
CLSN Celsion Corporation daily Stock Chart
CLSN [NASD]
Celsion Corporation
Index- P/E- EPS (ttm)-0.85 Insider Own0.30% Shs Outstand52.02M Perf Week-7.30%
Market Cap11.96M Forward P/E- EPS next Y-0.23 Insider Trans105.18% Shs Float52.02M Perf Month-14.81%
Income-22.10M PEG- EPS next Q-0.10 Inst Own6.60% Short Float11.49% Perf Quarter-1.46%
Sales0.50M P/S23.93 EPS this Y17.50% Inst Trans-24.96% Short Ratio2.87 Perf Half Y-72.81%
Book/sh0.14 P/B1.64 EPS next Y30.30% ROA- Target Price1.38 Perf Year-84.67%
Cash/sh0.09 P/C2.66 EPS next 5Y- ROE- 52W Range0.19 - 1.60 Perf YTD-24.32%
Dividend- P/FCF- EPS past 5Y29.80% ROI-229.70% 52W High-85.62% Beta1.47
Dividend %- Quick Ratio0.50 Sales past 5Y-24.20% Gross Margin- 52W Low24.32% ATR0.02
Employees19 Current Ratio0.50 Sales Q/Q0.00% Oper. Margin- RSI (14)40.98 Volatility8.89% 9.13%
OptionableYes Debt/Eq0.25 EPS Q/Q- Profit Margin- Rel Volume0.39 Prev Close0.24
ShortableNo LT Debt/Eq0.00 EarningsMay 12 BMO Payout- Avg Volume2.08M Price0.23
Recom2.00 SMA20-4.73% SMA50-14.10% SMA200-64.01% Volume821,505 Change-3.69%
Apr-10-17Resumed Rodman & Renshaw Buy $1.50
Nov-10-16Downgrade Maxim Group Buy → Hold
Jul-12-16Resumed H.C. Wainwright Buy $3
Jan-19-16Reiterated Maxim Group Buy $12 → $9
Jul-15-15Initiated Maxim Group Buy $12
Jan-10-14Resumed HC Wainwright Buy $5 → $8
Aug-16-12Reiterated Griffin Securities Buy $10 → $18
Feb-16-12Initiated Brean Murray Buy $7
Oct-26-11Initiated Rodman & Renshaw Mkt Outperform $6
Nov-11-09Initiated Needham Buy $7
May-26-17 04:05PM  Celsion Corporation Announces Stock Consolidation GlobeNewswire
09:39AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017 Capital Cube
May-20-17 01:06PM  Edited Transcript of CLSN earnings conference call or presentation 12-May-17 3:00pm GMT Thomson Reuters StreetEvents
May-12-17 09:00AM  Investor Network: Celsion Corporation to Host Earnings Call Accesswire
08:00AM  Celsion Corporation Reports First Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
May-05-17 08:00AM  Celsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12, 2017 GlobeNewswire
May-04-17 08:00AM  Celsion Updates Clinical Data from the OVATION Study in Newly Diagnosed  Advanced Ovarian Cancer Patients GlobeNewswire
Apr-27-17 03:51PM  ETFs with exposure to Celsion Corp. : April 27, 2017 Capital Cube
Apr-20-17 08:30AM  Celsion Announces Presentation of OVATION Study Findings at the Upcoming ASCO 2017 Annual Meeting GlobeNewswire +6.41%
Apr-17-17 12:50PM  ETFs with exposure to Celsion Corp. : April 17, 2017 Capital Cube
Apr-13-17 08:30AM  Celsion Corporation Reports Preclinical Results of ThermoDox® for the Treatment of Bladder Cancer Published in the International Journal of Hyperthermia GlobeNewswire
Apr-05-17 04:31PM  ETFs with exposure to Celsion Corp. : April 5, 2017 Capital Cube -6.86%
Mar-30-17 01:04PM  CELSION CORP Financials
Mar-29-17 08:46AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017 Capital Cube
Mar-24-17 04:36PM  CELSION CORP Files SEC form 10-K, Annual Report
Mar-16-17 09:03AM  CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
09:00AM  Celsion Corporation Reports Year End 2016 Financial Results and Provides Business Update GlobeNewswire
Mar-15-17 05:40PM  Forget Gilead, Buy These Small-Cap Biotech Stocks Instead Zacks +17.98%
Mar-09-17 09:00AM  Celsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16, 2017 GlobeNewswire +49.73%
Feb-27-17 08:30AM  Celsion Presents Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium GlobeNewswire +11.14%
Feb-21-17 08:00AM  Celsion Corp. Cancer Medications Insider Buying and Analysis Accesswire -11.00%
Feb-15-17 07:13AM  CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -33.33%
07:00AM  Celsion Corporation Announces $5.0 Million Public Offering GlobeNewswire
Jan-27-17 04:43PM  CELSION CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-19-17 12:40PM  ETFs with exposure to Celsion Corp. : January 19, 2017 Capital Cube
08:00AM  Celsion to Present Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium GlobeNewswire
Jan-18-17 08:00AM  Celsion Corporation Announces Issuance of Two New Patents for ThermoDox® GlobeNewswire -19.41%
Jan-17-17 08:00AM  Celsion Announces Continuing Positive Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients GlobeNewswire +30.77%
Dec-23-16 03:02PM  CELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
Dec-22-16 01:12PM  ETFs with exposure to Celsion Corp. : December 22, 2016
Dec-20-16 03:37PM  CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -25.13%
02:45PM  Celsion Corporation Announces $1.8 Million Registered Direct Offering GlobeNewswire
Dec-16-16 01:30PM  Celsion Corporation Announces Progress with ThermoDox® Development Efforts in China and Asia Pacific GlobeNewswire -7.86%
Dec-01-16 08:00AM  Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer GlobeNewswire
Nov-30-16 08:00AM  Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III OPTIMA Study of ThermoDox® for Primary Liver Cancer GlobeNewswire -13.07%
Nov-29-16 08:00AM  Celsion Corporation Announces Presentation of Results from Independent NIH Analysis of ThermoDox® plus Optimized RFA for the Treatment of Primary Liver Cancer at the 2016 RSNA Annual Meeting GlobeNewswire
Nov-16-16 12:58PM  ETFs with exposure to Celsion Corp. : November 16, 2016 +5.52%
Nov-15-16 11:47AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016
Nov-10-16 03:10PM  Celsion downgraded by Maxim Group
08:30AM  Celsion Announces Continuing Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Stage III and IV Ovarian Cancer Patients GlobeNewswire
08:13AM  CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:00AM  Celsion Corporation Reports Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
07:07AM  Q3 2016 Celsion Corp Earnings Release - Time Not Supplied
Nov-04-16 08:00AM  Celsion Corporation Announces Issuance of Two New U.S. Patents for its GEN-1 Immuno-Oncology Product GlobeNewswire
Nov-03-16 08:00AM  Celsion Corporation to Hold Third Quarter 2016 Financial Results Conference Call on Thursday, November 10, 2016 GlobeNewswire -9.18%
Oct-31-16 09:00AM  Celsion Presents Data on ThermoDox® plus Optimized RFA in Intermediate Primary Liver Cancer at the 3rd Asian Conference on Tumor Ablation (ACTA) GlobeNewswire
Oct-13-16 09:37AM  ETFs with exposure to Celsion Corp. : October 13, 2016
Oct-11-16 08:00AM  Celsion Announces Collaboration with the Childrens Research Institute to Evaluate the Use of ThermoDox® and High Intensity Focused Ultrasound in the Treatment of Solid Tumors in Children and Young Adults GlobeNewswire
Sep-15-16 08:00AM  Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer GlobeNewswire
Sep-12-16 10:41AM  ETFs with exposure to Celsion Corp. : September 12, 2016
08:00AM  Celsion Corporation Announces Independent NIH Analysis Showing Treatment with ThermoDox® Plus RFA May Significantly Improve Overall Survival of Patients with Primary Liver Cancer GlobeNewswire
Sep-08-16 04:32PM  CELSION CORP Files SEC form 8-K, Change in Directors or Principal Officers
Sep-07-16 08:00AM  Celsion Corporation to Present at Upcoming Investor Conferences GlobeNewswire
Aug-30-16 11:02AM  ETFs with exposure to Celsion Corp. : August 30, 2016
Aug-19-16 12:46PM  ETFs with exposure to Celsion Corp. : August 19, 2016
Aug-18-16 11:04AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
Aug-15-16 09:14AM  CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
09:00AM  Celsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
08:00AM  Celsion Corporation Announces Final Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer GlobeNewswire
07:07AM  Q2 2016 Celsion Corp Earnings Release - Time Not Supplied
Aug-09-16 09:00AM  Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Sign Technology Transfer, Manufacturing and Commercial Supply Agreement for the Development of its GEN-1 Immuno-Oncology Therapy GlobeNewswire
Aug-08-16 08:00AM  Celsion Corporation to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 15, 2016 GlobeNewswire
Jul-25-16 08:00AM  Celsion Announces Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Ovarian Cancer Patients GlobeNewswire
Jul-20-16 12:16PM  ETFs with exposure to Celsion Corp. : July 20, 2016
Jul-17-16 10:35AM  4 Speculative Biotech and Biohealth Analysts Calls for Huge Upside at 24/7 Wall St.
Jul-11-16 08:00AM  Celsion Announces Presentation Highlighting Phase III OPTIMA Study at the Asia-Pacific Primary Liver Cancer Expert Meeting GlobeNewswire
Jul-07-16 08:00AM  Celsion Corporation to Present at Cantor Fitzgeralds 2nd Annual Healthcare Conference GlobeNewswire
Jun-21-16 08:00AM  Celsion Announces the Potentially Curative Approach to Treatment of Primary Liver Cancer - The Focus of Hepatic Oncology Peer-Reviewed Article GlobeNewswire
Jun-17-16 05:01PM  CELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
Jun-15-16 04:54PM  CELSION CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matte
Jun-13-16 02:06PM  CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
02:03PM  Celsion Corporation Announces $6 Million Registered Direct Offering GlobeNewswire
Jun-07-16 11:08AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016
Jun-01-16 05:10PM  CELSION CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
May-24-16 08:00AM  Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting PR Newswire
May-16-16 08:18AM  CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:00AM  Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update PR Newswire
May-09-16 08:57AM  Should You Buy Celsion (CLSN) Ahead of Earnings?
08:00AM  Celsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16, 2016 PR Newswire
May-06-16 08:14AM  ARIAD (ARIA) to Report Q1 Earnings: Will the Stock Surprise? Zacks
May-02-16 08:00AM  Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study PR Newswire
Apr-26-16 08:00AM  Celsion Corporation Announces Enrollment of First Patient in the OPTIMA Study in China PR Newswire
Apr-19-16 08:00AM  Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin® and Doxil® PR Newswire +7.45%
Apr-12-16 08:00AM  Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer PR Newswire +5.22%
Apr-06-16 11:56AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2015 By the Numbers
09:23AM  Celsion Corp. :CLSN-US: Earnings Analysis: 2015 By the Numbers
Apr-01-16 09:49AM  Edited Transcript of CLSN earnings conference call or presentation 30-Mar-16 3:00pm GMT
Mar-30-16 11:00AM  Celsion Corp Earnings Call scheduled for 11:00 am ET today
08:28AM  CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:00AM  Celsion Corporation Reports Year End 2015 Financial Results and Provides Business Update PR Newswire
Mar-23-16 08:14AM  Celsion Corporation to Hold Year-End 2015 Financial Results Conference Call on Wednesday, March 30, 2016 at noodls
08:00AM  Celsion Corporation to Hold Year-End 2015 Financial Results Conference Call on Wednesday, March 30, 2016 PR Newswire
Mar-16-16 04:35PM  Celsion Announces Presentation of Preclinical Data for GEN-1 IL-12 Immunotherapy in Combination with Avastin® and Doxil® at the AACR Annual Meeting 2016 PR Newswire -5.71%
Mar-15-16 03:44PM  [$$] Cancer Therapy May See Major Shift at Barrons.com
Mar-07-16 08:00AM  Celsion Corporation Announces Launch of the OPTIMA Study in China PR Newswire +9.16%
Mar-01-16 08:00AM  Celsion Corporation Announces Issuance of Key U.S. Patent Covering its Novel TheraSilence RNA Program PR Newswire
Feb-15-16 03:20PM  Celsion (CLSN) Provides Pipeline Update, GEN-1 in Focus
Feb-12-16 08:00AM  Celsion Corporation Highlights Recent Pipeline Developments for its GEN-1 Immunotherapy Program and Provides Business Update PR Newswire
Jan-07-16 08:00AM  Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in Recurrent Ovarian Cancer PR Newswire
Jan-05-16 01:00PM  Exelixis Reveals Data on Cabozantinib for Kidney Cancer
Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martinez Alberto R JrDirectorFeb 21Buy0.2335,0008,050180,081Feb 22 09:17 AM
Martinez Alberto R JrDirectorFeb 15Buy0.2245,0009,675145,081Feb 16 11:35 AM
Martinez Alberto R JrDirectorNov 14Buy0.8610,0008,600100,081Nov 14 12:49 PM
Martinez Alberto R JrDirectorNov 11Buy0.9110,0009,10090,081Nov 14 10:21 AM
Tardugno Michael HChairman, President and CEOOct 07Buy1.1410,00011,400143,021Oct 11 09:13 AM
Martinez Alberto R JrDirectorAug 16Buy1.255,0006,25080,081Aug 17 09:11 AM
Tardugno Michael HChairman, President and CEOAug 16Buy1.255,0006,245133,021Aug 17 09:11 AM
Martinez Alberto R JrDirectorJun 17Buy1.355,0006,75075,081Jun 17 10:50 AM
Tardugno Michael HChairman, President and CEOJun 16Buy1.357,50010,125128,021Jun 16 04:52 PM